Table 1.
Gedatolisib partially reversed ABCB1-medaited MDR
| Drug | IC50 ± SD(RF) | |
|---|---|---|
| SW620 (μM) | SW620/ADR (μΜ) | |
| Doxorubicin | 0.042 ± 0.009 (1.00) | 10.653 ± 0.600 (253.64) |
| + Gedatolisib (0.1 μM) | 0.043 ± 0.009 (1.024) | 9.767 ± 0.424 (232.55) |
| + Gedatolisib (0.2 μM) | 0.039 ± 0.010 (0.928) | 6.431 ± 0.041 (153.12)* |
| + Verapamil (1 μM) | 0.038 ± 0.007 (0.905) | 0.412 ± 0.030 (9.80)* |
| Paclitaxel | 0.038 ± 0.005 (1.00) | 5.422 ± 0.556 (142.68) |
| + Gedatolisib (0.1 μM) | 0.040 ± 0.004 (1.05) | 4.379 ± 0.234 (115.24)* |
| + Gedatolisib (0.2 μM) | 0.037 ± 0.006 (0.97) | 3.273 ± 0.121 (86.13)* |
| + Verapamil (1 μM) | 0.042 ± 0.004 (1.10) | 0.090 ± 0.082 (2.37)* |
| Vincristine | 0.098 ± 0.009 (1.00) | 12.472 ± 1.263 (127.27) |
| + Gedatolisib (0.1 μM) | 0.088 ± 0.008 (0.90) | 10.863 ± 1.463 (110.85)* |
| + Gedatolisib (0.2 μM) | 0.091 ± 0.009 (0.93) | 5.324 ± 0.561 (54.33)* |
| + Verapamil (1 μM) | 0.087 ± 0.009 (0.89) | 0.231 ± 0.042 (2.36)* |
| Cisplatin | 3.234 ± 0.194 (1.00) | 3.536 ± 0.211 (1.09) |
| + Gedatolisib (0.1 μM) | 3.354 ± 0.213 (1.04) | 3.743 ± 0.263 (1.13) |
| + Gedatolisib (0.2 μM) | 3.453 ± 0.253 (1.07) | 3.243 ± 0.373 (0.8) |
| + Verapamil (1 μM) | 3.244 ± 0.210 (1.00) | 3.543 ± 0.262 (1.07) |
Resistance fold (RF) was calculated from dividing the IC50 values of SW620/ADR cells by the IC50 values of SW620 cells in the presence or absence of gedatolisib or verapamil
*Presents when p value is < 0.05. Data was showed with mean ± SD, which is representative for at least three independent experiments